[1] Tanaka A, Mori M, Matsumoto K, et al. An increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res, 2019,19:133-135. [2] Valgeirsson KB, Hreinsson JP, Bjrnsson ES. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs. Liver Int, 2019, 39:193-199. [3] Lauri, Puustinen, Nina, et al. Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland. Dig Liver Dis, 2019, 51:1294-1299. [4] de Moraes Falco LT, Terrabuio DRB, Diniz MA, et al. Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial. JGH Open, 2019, 4:371-377. [5] Chapman RW, Aspinall RJ, Trivedi P, et al. Challenges in the use of corticosteroids in the management of autoimmune hepatitis. Br J Hosp Med (Lond), 2019, 80:594-599. [6] A, J, Czaja. Emerging Treatments for Autoimmune Hepatitis. C Targets Inflamm Allergy, 2002, 38: 150-155. [7] Brand FVD, Boer YD, Nieuwkerk KV, et al. FRI-063-Low-dose prednisone increases the risk of adverse events in autoimmune hepatitis patients. J Hepatology, 2019, 70:e413. [8] Llovet LP, Horta D, Eliz MG, et al. Pregnancy and autoimmune hepatitis: presentation and outcomes. J Hepatology, 2018, 68:S233. [9] Prasad D, Poddar U, Kanaujia V, et al. Effect of Long-term Oral Steroids on Intraocular Pressure in Children With Autoimmune Hepatitis: a Prospective Cohort Study. J Glaucoma, 2019, 28:492-495. [10] Ashnila J, Hirschfield GM. Autoimmune hepatitis and complexities in management. Frontline Gastroenterol, 2018, 10:77-87. [11] Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.Gastroenterology, 1972,63:820-833. [12] Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis.Lancet, 1973,1:735-737. [13] Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol, 2010, 53:191-198. [14] Purnak T, Efe C, Kav T, et al. Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis. Dig Dis Sci, 2017, 12: 193-195. [15] Swann J W, Szladovits B, Threlfall A J, et al. Randomised controlled trial of fractionated and unfractionated prednisolone regimens for dogs with immune-mediated haemolytic anaemia. Vet Rec, 2019, 184:vetrec-2018-105104. |